Tropical Medicine Department, University of Kinshasa, Kinshasa, Kinshasa, Democratic Republic of the Congo.
Vaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Wilrijk, Antwerp, Belgium.
PLoS One. 2023 Sep 1;18(9):e0286479. doi: 10.1371/journal.pone.0286479. eCollection 2023.
A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens.
Serum samples were collected in a cohort of HCPs and frontliners (n = 698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay.
The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7-2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0-1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9) samples using FANG ELISA.
In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.
在刚果民主共和国（DRC）曾受埃博拉病毒病（EVD）影响的一个地区，对卫生保健工作者（HCPs）和一线人员进行了血清学调查，以评估对埃博拉病毒抗原的血清反应性。
在 EBL2007 疫苗试验（2019 年 12 月至 2022 年 10 月）的队列中收集了 HCPs 和一线人员（n = 698）的血清样本。使用 Filovirus Animal Nonclinical Group（FANG）ELISA 或 Luminex 多重分析试剂盒确认对 EBOV 呈血清反应性的标本。
使用 Luminex 分析，在至少两种 EBOV-Mayinga（m）抗原中，有 10 份（1.4%：95%置信区间，0.7-2.6）样本为 GP-EBOV-m + VP40-EBOV-m，有 2 份（0.3%：95%置信区间，0.0-1.0）样本为 VP40-EBOV-m + NP-EBOV-m 呈血清反应性。使用 FANG ELISA 观察到 59 份（8.5%：95%CI，6.5-10.9）样本对 GP-EBOV-Kikwit（k）呈血清反应性。
与之前的血清学调查相比，在刚果民主共和国博恩代参加 EBL2007 埃博拉疫苗试验的 HCP 和一线人员中，血清阳性率较低。这突出表明，在埃博拉病毒流行地区进行埃博拉病毒血清学调查时，需要标准化抗体检测和截断值，以避免报告的埃博拉病毒血清阳性率的广泛范围。
